GlassScriptPhysician profile
Luke Y Ouyang
NPI 1629001318
$8,522.81
in general payments reported to CMS, 2019-2025
41 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,611 · 2020: $1,484 · 2021: $1,632 · 2022: $1,528 · 2023: $1,496 · 2024: $540 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,268.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $993.91 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $748.81 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $687.72 | 2019-2025 | Farxiga, Breztri |
| Pfizer INC. | $604.00 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $544.24 | 2019-2023 | Spravato, Xarelto |
| Merck Sharp & Dohme LLC | $511.54 | 2019-2023 | Belsomra, Steglatro, Steglujan |
| Amgen INC. | $498.44 | 2019-2024 | Repatha, Otezla |
| Kowa Pharmaceuticals America, INC. | $482.20 | 2019-2021 | |
| Abbvie INC. | $459.36 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $414.21 | 2019-2025 | Jardiance, Ofev |
| Lilly USA, LLC | $376.08 | 2019-2025 | Jardiance, Mounjaro, Kisunla |
| Amarin Pharma, INC. | $288.77 | 2019-2022 | |
| Abbott Laboratories | $197.70 | 2022-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $195.13 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $182.58 | 2020-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Ouyang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.